Stephan Kremers

4.6k total citations · 1 hit paper
21 papers, 1.4k citations indexed

About

Stephan Kremers is a scholar working on Hematology, Oncology and Electrical and Electronic Engineering. According to data from OpenAlex, Stephan Kremers has authored 21 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 6 papers in Oncology and 6 papers in Electrical and Electronic Engineering. Recurrent topics in Stephan Kremers's work include Acute Myeloid Leukemia Research (6 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Phase-change materials and chalcogenides (3 papers). Stephan Kremers is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Phase-change materials and chalcogenides (3 papers). Stephan Kremers collaborates with scholars based in Germany, Austria and Czechia. Stephan Kremers's co-authors include Matthias Wuttig, K.V. Shportko, Michael Woda, Dominic Lencer, John Robertson, Hartmut Döhner, Hans Salwender, Axel Glasmacher, Heinz A. Horst and W. Grimminger and has published in prestigious journals such as Nature Materials, Journal of Clinical Oncology and Blood.

In The Last Decade

Stephan Kremers

20 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Resonant bonding in crystalline phase-change materials

2008 925 citations K.V. Shportko, Stephan Kremers et al. Nature Materials profile →

Peers

Countries citing papers authored by Stephan Kremers

Since Specialization

Citations

This map shows the geographic impact of Stephan Kremers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephan Kremers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephan Kremers more than expected).

Fields of papers citing papers by Stephan Kremers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephan Kremers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephan Kremers. The network helps show where Stephan Kremers may publish in the future.

Co-authorship network of co-authors of Stephan Kremers

This figure shows the co-authorship network connecting the top 25 collaborators of Stephan Kremers. A scholar is included among the top collaborators of Stephan Kremers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephan Kremers. Stephan Kremers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group 2024 ·Annals of Hematology ·(unknown), Martin Hoffmann, Vindi Jurinović, (unknown), Michael Unterhalt, (unknown), (unknown), Ulrich Dührsen, (unknown), Stephan Kremers, Hans‐Walter Lindemann, (unknown), Wolfgang Hiddemann, Eva Hoster, Martin Dreyling, (unknown)	0
2	Low-Dose Azacitidine, Pioglitazone and All-Trans Retinoic Acid Versus Standard-Dose Azacitidine in Patients ≥ 60 Years with Acute Myeloid Leukemia Refractory to Standard Induction Chemotherapy (AMLSG 26-16/AML-ViVA): Results of the Safety Run-in Phase I 2019 ·Blood ·Daniel Heudobler, Sebastian Klobuch, Florian Lüke, J. Hahn, Matthias Grube, Stephan Kremers, Thomas Südhoff, Jörg Westermann, (unknown), Peter Paschka, Gauthier Bouche, Hartmut Döhner, Wolfgang Herr, Simone Thomas, Albrecht Reichle	9
3	Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study 2017 ·Annals of Hematology ·Martin Kropff, Martin Vogel, Guido Bisping, Rudolf Schlag, Rudolf Weide, Wolfgang Knauf, (unknown), G. Kojouharoff, Stephan Kremers, Wolfgang E. Berdel	14
4	Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group 2015 ·Leukemia & lymphoma ·Valentin Goede, Raymonde Busch, Jasmin Bahlo, (unknown), Stephan Kremers, Lothar Müller, (unknown), Rudolf Schlag, Burkhard Schmidt, Ursula Vehling‐Kaiser, Ulrich Wedding, S. Stilgenbauer, Michael Hallek	3
5	Bortezomib and Low-Dose Dexamethasone with or without Continuous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma: Final Results of a National Multicenter Randomized Controlled Phase III Study 2014 ·Blood ·Martin Kropff, Martin Vogel, (unknown), Rudolf Schlag, Lothar Müller, Rudolf Weide, Wolfgang Knauf, Thomas Decker, (unknown), G. Kojouharoff, Stephan Kremers, Wolfgang E. Berdel	5
6	Influence of Partial Substitution of Te by Se and Ge by Sn on the Properties of the Blu-ray Phase-Change Material Ge₈Sb₂Te₁₁ 2012 ·Chemistry of Materials ·(unknown), Christine Koch, Wolfgang Bensch, Peter Zalden, (unknown), Stephan Kremers, Matthias Wuttig, Ulrich Schürmann, Lorenz Kienle, Thomas Leichtweiß, Jürgen Janek, (unknown)	38
7	The influence of a temperature dependent bandgap on the energy scale of modulated photocurrent experiments 2011 ·Journal of Applied Physics ·Jennifer Luckas, Stephan Kremers, Daniel Krebs, Martin Salinga, Matthias Wuttig, Christophe Longeaud	32
8	Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma 2011 ·Blood ·Boris Böll, Henning Bredenfeld, Helen Görgen, Teresa Halbsguth, Hans Theodor Eich, Martin Soekler, Jana Marková, Ulrich Keller, Ullrich Graeven, Stephan Kremers, Michael Geißler, Guido Trenn, Michael Fuchs, Bastian von Tresckow, Dennis A. Eichenauer, Peter Borchmann, Andreas Engert	58
9	Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33) 2010 ·Supportive Care in Cancer ·(unknown), Sibylle Loibl, Volkmar Mueller, Gϋnter von Minckwitz, Bettina Conrad, (unknown), Stephan Kremers, Helmut Forstbauer, (unknown), Valentina Nekljudova, Volker Moebus	19
10	Characterization of amorphous organic thin films, determination of precise model for spectroscopic ellipsometry measurements 2010 ·Applied Surface Science ·(unknown), (unknown), Phenwisa Niyamakom, Stephan Kremers, (unknown), M. Heuken, Matthias Wuttig	8
11	Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A 2010 ·Journal of Clinical Oncology ·Richard F. Schlenk, Konstanze Döhner, Silja Mack, (unknown), Franz J. Király, Katharina S. Götze, Frank Hartmann, Heinz A. Horst, Elisabeth Koller, Andreas Petzer, W. Grimminger, Guido Kobbe, Axel Glasmacher, Hans Salwender, Heinz Kirchen, Detlef Haase, Stephan Kremers, Axel Matzdorff, Axel Benner, Hartmut Döhner	158
12	Prospective Phase III Trial of Valproic acid (VPA) In Combination with All-Trans Retinoic Acid (ATRA) and Intensive Induction Therapy for AML In Older Patients: The German-Austrian AMLSG 06-04 Study 2010 ·Blood ·Michela Tassara, (unknown), Konstanze Döhner, Marie von Lilienfeld‐Toal, Gerhard Held, Katharina S. Götze, Heinz A. Horst, Sibylla Wilhelm, Stephan Kremers, Elisabeth Koller, Daniela Späth, Silja Mack, (unknown), Martin Göttlicher, Hartmut Döhner, Richard F. Schlenk	1
13	Optische Eigenschaften von Phasenwechselmaterialien für zukünftige optische und elektronische Speicheranwendungen 2009 ·RWTH Publications (RWTH Aachen) ·Stephan Kremers, Matthias Wuttig	7
14	Resonant bonding in crystalline phase-change materials breakdown → 2008 ·Nature Materials ·K.V. Shportko, Stephan Kremers, Michael Woda, Dominic Lencer, John Robertson, Matthias Wuttig	925
15	Structure and morphology of perylene films grown on different substrates 2008 ·Journal of Applied Physics ·(unknown), Phenwisa Niyamakom, (unknown), (unknown), Stephan Kremers, (unknown), Matthias Wuttig	12
16	Evolution of dislocations in perylene films with thickness and deposition rate 2007 ·physica status solidi (RRL) - Rapid Research Letters ·(unknown), Phenwisa Niyamakom, (unknown), Stephan Kremers, Thomas Michely, Matthias Wuttig	14
17	Dose-Dense Rituximab in Combination with Biweekly CHOP-14 for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Phase-I/II and Pharmacokinetic Study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). 2006 ·Blood ·Viola Poeschel, Maike Nickelsen, Mathias Hänel, Stephan Kremers, Swen Weßendorf, Hartmut Eimermacher, Norma Peter, Michael Wenger, Marcel Reiser, Norbert Schmitz, Michael Pfreundschuh	8
18	All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct To Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of Consecutive Phase II Studies of the AMLSG. 2006 ·Blood ·Richard F. Schlenk, Konstanze Döhner, (unknown), Francisco del Valle, (unknown), Ingo G.H. Schmidt‐Wolf, H. Pralle, Katharina S. Götze, Elisabeth Koller, David Nachbaur, (unknown), Walter Fiedler, Detlef Haase, Stephan Kremers, Matthias Theobald, Axel Matzdorff, Arnold Ganser, Hartmut Döhner	1
19	All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct To Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of Consecutive Phase II Studies of the AMLSG. 2005 ·Blood ·Richard F. Schlenk, Konstanze Doehner, (unknown), Frank Hartmann, (unknown), Axel Glasmacher, H. Pralle, Katharina Goetze, Elisabeth Koller, Guenther Gastl, (unknown), Hans Salwender, Heinz Kirchen, Detlef Haase, Stephan Kremers, Christoph Nerl, Matthias Theobald, Axel Matzdorff, Arnold Ganser, Hartmut Doehner, (unknown)	2
20	Participation in a sigmoidoscopic colorectal cancer screening program: a pilot study. 2000 ·PubMed ·Stephan Kremers, Ilse Mesters, (unknown), Ben van den Borne, R.W. Stockbrügger	32

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact